check_circleStudy Completed

Clinical Pharmacology

Bayer Identifier:

18359

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2015-002612-32

EU CT Number:

Not Available
BAY59-7939, comparison of PK of Rivaroxaban and Apixaban

Trial purpose

To assess the plasma pharmacokinetics (PK) of
rivaroxaban and apixaban after multiple dosing and after
discontinuation of both.

Key Participants Requirements

Sex

Male

Age

18 - 55 Years
  • - Healthy male white subjects age 18 to 55 years (inclusive) with a
    body mass index above or equal 18.0 kg/m² and below or equal
    29.9 kg/m²

Trial summary

Enrollment Goal
N/A
Trial Dates
September 2015 - February 2016
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Mönchengladbach, 41061, Germany

Trial design

A randomized, cross-over study evaluating the PK/ PD relationship after oral doses of 20 mg rivaroxaban once daily and 5 mg apixaban twice daily over 7 days in healthy male subjects
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.